4.5(top 10%)
impact factor
3.4K(top 5%)
papers
105.9K(top 5%)
citations
116(top 5%)
h-index
5.0(top 10%)
extended IF
4.7K
all documents
111.8K
doc citations
155(top 5%)
g-index

Top Articles

#TitleJournalYearCitations
1Why do trials for Alzheimer’s disease drugs keep failing? A discontinued drug perspective for 2010-2015Expert Opinion on Investigational Drugs2017499
2Targeting STAT3 in cancer: how successful are we?Expert Opinion on Investigational Drugs2009364
3Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatmentExpert Opinion on Investigational Drugs2006363
4Pregabalin: a new anxiolyticExpert Opinion on Investigational Drugs2003297
5Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphomaExpert Opinion on Investigational Drugs2007291
6Histone deacetylase inhibitors: discovery and development as anticancer agentsExpert Opinion on Investigational Drugs2005284
7Therapeutic applications of carbon monoxide-releasing moleculesExpert Opinion on Investigational Drugs2005275
8Berberine: a potential phytochemical with multispectrum therapeutic activitiesExpert Opinion on Investigational Drugs2010272
9Ebselen: prospective therapy for cerebral ischaemiaExpert Opinion on Investigational Drugs2000259
10Squalene: potential chemopreventive agentExpert Opinion on Investigational Drugs2000255
11Terpenoids: natural products for cancer therapyExpert Opinion on Investigational Drugs2012240
12Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitusExpert Opinion on Investigational Drugs2001237
13Clinical overview on Lipoplatin™: a successful liposomal formulation of cisplatinExpert Opinion on Investigational Drugs2009232
14A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P)Expert Opinion on Investigational Drugs2009228
15PTP1B inhibitors as potential therapeutics in the treatment of Type 2 diabetes and obesityExpert Opinion on Investigational Drugs2003225
16Antioxidants as treatment for neurodegenerative disordersExpert Opinion on Investigational Drugs2002220
17Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular diseaseExpert Opinion on Investigational Drugs2015215
18Histone deacetylase inhibitors: from target to clinical trialsExpert Opinion on Investigational Drugs2002214
19The immunotherapeutic potential of melatoninExpert Opinion on Investigational Drugs2001204
20Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetesExpert Opinion on Investigational Drugs2003200
21Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumorsExpert Opinion on Investigational Drugs2018200
22Antimicrobial properties of porphyrinsExpert Opinion on Investigational Drugs2001197
23Do STAT3 inhibitors have potential in the future for cancer therapy?Expert Opinion on Investigational Drugs2017195
24Histone deacetylase inhibitors in cancer therapyExpert Opinion on Investigational Drugs2007194
25Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetesExpert Opinion on Investigational Drugs2003190
26Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and developmentExpert Opinion on Investigational Drugs2000189
27Zaleplon - a review of a novel sedative hypnotic used in the treatment of insomniaExpert Opinion on Investigational Drugs2000189
28Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancerExpert Opinion on Investigational Drugs2009187
29Mechanism of action of the oxazolidinone antibacterial agentsExpert Opinion on Investigational Drugs1999186
30Novel therapeutic usage of low-dose doxepin hydrochlorideExpert Opinion on Investigational Drugs2007183
31Daptomycin: a novel agent for Gram-positive infectionsExpert Opinion on Investigational Drugs1999182
32The therapeutic potential of flavonoidsExpert Opinion on Investigational Drugs2000178
33Cilengitide: an integrin-targeting arginine–glycine–aspartic acid peptide with promising activity for glioblastoma multiformeExpert Opinion on Investigational Drugs2008178
34Targeting AKT for cancer therapyExpert Opinion on Investigational Drugs2019178
35Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?Expert Opinion on Investigational Drugs2004177
36Aldose reductase inhibitors: therapeutic implications for diabetic complicationsExpert Opinion on Investigational Drugs1999175
37Indisulam: an anticancer sulfonamide in clinical developmentExpert Opinion on Investigational Drugs2003169
38Duloxetine: a serotonin-noradrenaline re-uptake inhibitor for the treatment of stress urinary incontinenceExpert Opinion on Investigational Drugs2003166
39The benzodiazepine binding site of GABAAreceptors as a target for the development of novel anxiolyticsExpert Opinion on Investigational Drugs2005166
40Triclabendazole for the treatment of fascioliasis and paragonimiasisExpert Opinion on Investigational Drugs2005165
41From chemoprevention to chemotherapy: common targets and common goalsExpert Opinion on Investigational Drugs2004163
42VEGF/VEGFR signalling as a target for inhibiting angiogenesisExpert Opinion on Investigational Drugs2007159
43MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapyExpert Opinion on Investigational Drugs2012159
44The therapeutic potential of CRF1 antagonists for anxietyExpert Opinion on Investigational Drugs2004157
45Histone deacetylase inhibitors: possible implications for neurodegenerative disordersExpert Opinion on Investigational Drugs2008156
46Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and presentExpert Opinion on Investigational Drugs2014154
47Curcumin and neurodegenerative diseases: a perspectiveExpert Opinion on Investigational Drugs2012153
48The role of growth factors in the pathogenesis of diabetic retinopathyExpert Opinion on Investigational Drugs2004151
49Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directionsExpert Opinion on Investigational Drugs2014151
50Leuprolide acetate: a drug of diverse clinical applicationsExpert Opinion on Investigational Drugs2007146